Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

Summary

This is a randomized, placebo-controlled Phase 2 trial consisting of up to 300 subjects with either psoriasis or atopic dermatitis. In this trial BMX-010 will be topically applied twice daily for up to 28 days.

Timeline

Start

2018-01-02

Primary completion

2021-07-24

Completion

2021-07-24

Drugs

Indications